Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.08.2014 | case report | Ausgabe 15-16/2014

Wiener klinische Wochenschrift 15-16/2014

Levosimendan reverses right-heart failure in a 51-year-old patient after heart transplantation

Wiener klinische Wochenschrift > Ausgabe 15-16/2014
MD, PhD Stjepan Barisin, MD Viktor Djuzel, MD, PhD Ana Barisin, MD, PhD Igor Rudez


Primary graft failure in the early postoperative period after heart transplantation, remains a main cause of a poor outcome. Current treatment options include pharmacological (catecholamines and phosphodiesterase inhibitors) and mechanical assist device support. Pharmacological support with catecholamines is related to elevated myocardial oxygen consumption and regional hypoperfusion leading to organ damage. On the other hand, levosimendan, as a calcium-sensitizing agent increases cardiac contractility without altering intracellular Ca2+ levels and increase in oxygen demand.
We present a case of a 51-year-old man, who was suffering from acute right-heart failure in the early postoperative period after heart transplantation. As a rescue therapy at the late stage of a low cardiac output state, levosimendan was started as continuous infusion at 0.1 μg/kg/min for 12 h and thereafter, at 0.2 μg/kg/min for the following 36 h. Levosimendan demonstrated an advanced pharmacological option as was portrayed in this case, where the right ventricle was under a prolonged severe depression and acutely overloaded after heart transplantation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 15-16/2014

Wiener klinische Wochenschrift 15-16/2014 Zur Ausgabe



mitteilungen der gesellschaft der ärzte in wien